LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Theravance Biopharma Inc

Open

13.88 -0.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.79

Max

14.03

Belangrijke statistieken

By Trading Economics

Inkomsten

68M

55M

Verkoop

11M

26M

K/W

Sectorgemiddelde

57.833

35.733

EPS

-0.173

Winstmarge

209.334

Werknemers

97

EBITDA

87M

75M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+31.9% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

129M

699M

Vorige openingsprijs

14.52

Vorige sluitingsprijs

13.88

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Theravance Biopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2025, 10:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

2 jun 2025, 10:00 UTC

Acquisities, Fusies, Overnames

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

Peer Vergelijking

Prijswijziging

Theravance Biopharma Inc Prognose

Koersdoel

By TipRanks

31.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.4 USD  31.9%

Hoogste 26 USD

Laagste 13 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Theravance Biopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technische score

By Trading Central

9.77 / 10.39Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
help-icon Live chat